"Understanding the results of glucose clamp studies"
Insights from Dr. Tim Heise, our expert on glucose clamping:
You will benefit by learning about:
- Impact of poor clamp quality on the reported GIR-results
- Amelioration of glucose clamp quality, in particular through improvement of algorithms for calculation of the optimal GIR by Profil
- Derivation of outcome parameters of clamp studies such as onset of action or duration of action and their dependence on clamp design and clamp quality
- Different PD parameters describing insulin variability
Glucose clamp studies are the gold standard for the assessment of pharmacodynamic (PD) characteristics of blood-glucose lowering agents, in particular novel insulins and insulin biosimilars. In a glucose clamp the blood-glucose lowering effect of e.g. a novel insulin is antagonised by means of a variable glucose infusion of glucose, so that blood glucose concentrations are “clamped” at a pre-defined target level. If (and only, if) blood glucose concentrations are kept close to target, the amount of glucose infused (i.e., the glucose infusion rate GIR) is a good indicator of the PD effect.
However, most publications only report GIR-values, but do not show blood glucose data or report clamp quality parameters such as blood glucose variability or the mean deviation from target level. This webinar will show how poor clamp quality might impact the report GIR-results and will demonstrate how we at Profil perpetually try to further ameliorate glucose clamp quality, in particular through improved algorithms for calculation of the optimal GIR.
Still, many physicians and scientists find it difficult to understand the outcome of glucose clamp studies as GIR is not easily translatable into blood glucose values. Furthermore, some outcome parameters of clamp studies such as onset of action or duration of action are not fully in line with clinical experience of when insulins start or stop working. The webinar will explain how these parameters are derived and why they are dependent on clamp design and clamp quality.
Finally, the webinar will shed light on the different PD parameters describing insulin variability which has been a matter of some confusion and controversial discussions since conflicting results were reported for some basal insulins.
Meet the presenter
Dr. Tim Heise has more than 25 years of experience in both clinical research and clinical care in diabetes and obesity. He has published well over 150 scientific papers and reviews with a focus on the pharmacology of insulin and anti-diabetic drugs. Dr Heise is a member of the Editorial Board for Diabetes, Obesity and Metabolism and he takes a strong interest in evidence-based medicine.